Phathom Pharmaceuticals, Inc. - Form 8-K Summary
Business Context and Reporting Period
Phathom Pharmaceuticals, Inc. (PHAT), a Delaware corporation, filed this Current Report on Form 8-K on November 7, 2024. The filing serves to announce the company's financial results for the quarter ended September 30, 2024, via a press release attached as Exhibit 99.1.
Key Financial Metrics
The provided text is a cover sheet and does not contain specific financial data. It references a press release (Exhibit 99.1) for details on revenue, profit, cash flow, margins, debt, and liquidity. Consequently, the filing text does not provide a clear value for any specific financial metric.
Material Changes
No material changes versus the prior comparable period are detailed in this document. The filing solely acts as a notification that the Q3 2024 results have been issued.
Guidance, Outlook, and Risks
This document does not contain management commentary, guidance, outlook, or specific risk factors. It notes that the information in the report and Exhibit 99.1 is not deemed "filed" for purposes of Section 18 of the Exchange Act and is not incorporated by reference into other filings unless expressly stated.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for actual Q3 2024 financial figures.
- Verify the company's status as an emerging growth company and its election regarding extended transition periods for accounting standards.
- Confirm the trading symbol (PHAT) and exchange (Nasdaq Global Select Market) for accurate market data retrieval.
- Check subsequent filings for the full text of the press release if not immediately available.